Gilead Sciences, Inc. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Gilead Sciences, Inc. is a biopharmaceutical company focused on HIV, viral hepatitis, oncology, and inflammation. The company operates as a single operating segment managed on an entity-wide basis.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $7,082 million | $6,954 million | $13,749 million | $13,640 million |
| Net Income (Attributable to Gilead) | $1,960 million | $1,614 million | $3,275 million | $(2,556) million |
| Diluted EPS | $1.56 | $1.29 | $2.61 | $(2.05) |
| Operating Cash Flow (YTD) | $2,584 million (2025) vs $3,544 million (2024) | |||
| Cash & Equivalents (End of Period) | $5,144 million | |||
| Total Debt (Net) | $24,946 million | |||
| Product Gross Margin | 78.7% | 77.7% | 77.7% | 77.2% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 2% in Q2 and 1% YTD compared to 2024. Growth was driven by higher HIV sales (Biktarvy +9%, Descovy +35%) and Trodelvy (+14% in Q2), partially offset by declines in Veklury (-44%) and HCV products.
- Profitability Improvement: Net income turned from a loss of $2.6 billion YTD 2024 to a profit of $3.3 billion YTD 2025. This reversal is primarily due to the absence of a $3.9 billion acquired IPR&D expense (CymaBay acquisition) and a $2.4 billion IPR&D impairment (Trodelvy NSCLC) recorded in Q1 2024.
- Current Period Charges: Q2 2025 included a $190 million IPR&D impairment charge related to bulevirtide due to competitive market data. Acquired IPR&D expenses were $315 million YTD, largely driven by a $250 million upfront payment for the LEO Pharma collaboration.
- Equity Gains: Other income improved significantly due to net unrealized gains on equity securities in 2025 compared to losses in 2024.
Guidance, Outlook, and Risks
- Capital Allocation: The company continues to prioritize R&D, dividends, and share repurchases. In July 2025, the Board authorized a new $6.0 billion stock repurchase program. A quarterly dividend of $0.79 per share was declared for payment in September 2025.
- Regulatory & Tax Environment: The company is assessing the impact of the "One Big Beautiful Bill" (OBBB) Act enacted in July 2025, which restores immediate expensing of domestic R&D. The company does not expect a material impact on results of operations.
- Key Risks:
- Patent Litigation: Ongoing lawsuits against generic manufacturers (Lupin, Laurus, Cipla, Aspiro) regarding Biktarvy and Veklury. A trial regarding Biktarvy is scheduled for October 2025.
- Product Liability: Approximately 23,000 active plaintiffs in lawsuits alleging kidney, bone, and tooth injuries from HIV products (Viread, Truvada, etc.).
- Development Risks: FDA placed a clinical hold on HIV treatment trials for GS-1720 and GS-4182 in June 2025.
- Impairment Risk: Continued monitoring of IPR&D assets for Trodelvy (NSCLC) and bulevirtide; further impairments may be recorded if assumptions change.
Investor Verification Checklist
- IPR&D Impairments: Verify the assumptions used for the $190 million bulevirtide impairment and monitor for potential future charges on Trodelvy NSCLC assets.
- Generic Competition: Track the October 2025 trial date for Biktarvy patent litigation and the status of Veklury generic challenges.
- Cash Flow Usage: Review the $1.3 billion federal income tax payment made in Q2 related to the Tax Cuts and Jobs Act transition tax.
- Collaboration Milestones: Monitor the LEO Pharma STAT6 program progress following the $250 million upfront payment.
- Product Mix: Assess the sustainability of HIV revenue growth (Biktarvy/Descovy) against the declining trajectory of Veklury and HCV products.